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Notice of retraction and replacement: Hofmann et al., Effect of intranasal oxytocin 
administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies. 
Psychiatry Research. 2015;228:708-714.  
 
To the Editors: 
 
We have discovered several significant errors in our published meta-analysis comparing 
the effect of intranasal oxytocin versus placebo administration on psychiatric symptoms (Effect 
of Intranasal Oxytocin Administration on Psychiatric Symptoms: A Meta-Analysis of Placebo-
Controlled Studies. Psychiatry Research. 2015;228:708-714.)  
Correcting these errors changed the main result of this study. The corrected result is that 
oxytocin is not more efficacious for psychiatric symptoms compared to placebo. Our overall 
placebo-controlled effect size, which was previously reported as significant, is no longer 
significant. In addition, none of the symptom-specific effects of oxytocin versus placebo are 
significant.  
The primary error with our original data was the misspecification of the direction of 
several outcomes included in the meta-analysis. The reason for the error is that the program we 
used, Comprehensive Meta-Analysis, requires users to manually enter the direction of the 
effects. We mistakenly assumed that individuals in the placebo group would never show greater 
reductions in psychiatric symptoms than individuals receiving oxytocin. Therefore, we assumed 
that the direction of the placebo controlled effect size of oxytocin would never be negative. 
However this assumption was incorrect for 7 effect size estimates. In addition, we discovered 
some more minor data extraction errors. 
The corrected placebo-controlled effect size is Hedges’ g = 0.11, p = 0.51. The direction 
of the effect size was also incorrect for 7 symptom measures (out of 28 total measures), which 
were used to calculate symptom-specific effects of oxytocin vs. placebo (e.g., on depression, 
anxiety, autism/repetitive behaviors, psychotic symptoms, and general psychopathology). The 
corrected effect sizes for the symptom domains are the following: depression (Hedges’ g = -0.01, 
p = 0.96), anxiety (Hedges’ g = -0.04, p = 0.86), autism/repetitive behaviors (Hedges’ g = 0.10, p 
= 0.68), psychotic symptoms (Hedges’ g = 0.49, p = 0.10), and general psychopathology 
(Hedges’ g = 0.15, p = 0.47). Whereas our data previously indicated that oxytocin had some 
potential benefit for reducing depression, anxiety, psychotic symptoms, and general 
psychopathology, we now conclude that oxytocin has no benefit for any of these symptom 
domains.  
We greatly apologize to the journal, the reviewers, and readers for the errors in the 
original article, and we thank the readers who brought the errors to our attention. We would like 
to urge researchers to be mindful of the direction of the effect sizes, especially when using 
certain software programs, such as the Comprehensive Meta-Analysis program. Effect sizes and 
effect size directions should always be carefully examined manually, even when using a software 
program and it cannot be assumed that the placebo group is never superior to the treatment 
group.  
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